Sandoz, Liquidia score $137M win against United in years-long generic Remodulin dispute

Sandoz and United Therapeutics’ yearslong dispute over a generic to pulmonary arterial hypertension med treprostinil has swung in Sandoz’s favor with a New Jersey district court deciding that the former Novartis subsidiary is owed damages from lost profits stemming from a 2015 breach of contract.